Blood Research

Cited by CrossRef (7)

  1. Julian Baumeister, Nicolas Chatain, Alexandros Marios Sofias, Twan Lammers, Steffen Koschmieder. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives. Cells 2021;10:3551
    https://doi.org/10.3390/cells10123551
  2. Farah Perveen Mughal, Ann Christina Bergmann, Ha Uyen Buu Huynh, Sarah Hyllekvist Jørgensen, Inaam Mansha, Meliha Kesmez, Patrick Mark Schürch, Alexandre Pierre André Theocharides, Paul Robert Hansen, Tina Friis, Morten Orebo Holmström, Evaldas Ciplys, Rimantas Slibinskas, Peter Højrup, Gunnar Houen, Nicole Hartwig Trier. Production and Characterization of Peptide Antibodies to the C-Terminal of Frameshifted Calreticulin Associated with Myeloproliferative Diseases. IJMS 2022;23:6803
    https://doi.org/10.3390/ijms23126803
  3. Chiara Baldini, Francesca Romana Moriconi, Sara Galimberti, Peter Libby, Raffaele De Caterina. The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. 2021;42:4389
    https://doi.org/10.1093/eurheartj/ehab447
  4. Niccolò Bartalucci, Lorenzo Galluzzi. Cellular and Molecular Aspects of Myeloproliferative Neoplasms – Part B. 2021.
    https://doi.org/10.1016/S1937-6448(22)00019-3
  5. Nicole Kucine, Jewell A. Jessup, Todd M. Cooper, Ray W. Urbanski, E. Anders Kolb, Linda M. S. Resar. Position paper: The time for cooperative group study of ropeginterferon alfa‐2b in young patients with myeloproliferative neoplasms is now. Pediatric Blood & Cancer 2023;70
    https://doi.org/10.1002/pbc.30559
  6. Niccolò Bartalucci, Lorenzo Galluzzi. Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A. 2023.
    https://doi.org/10.1016/S1937-6448(21)00127-1
  7. Sung-Yong Kim. Adverse effects of hydroxyurea used for the treatment of myeloproliferative neoplasms. J Korean Med Assoc 2023;66:253
    https://doi.org/10.5124/jkma.2023.66.4.253
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd